Kura Oncology Stock Valuation

KURA
 Stock
  

USD 14.98  0.28  1.90%   

Do you wonder what the value of Kura Oncology is? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Kura Oncology, is its stock price multiplied by the total number of shares outstanding, calculating Kura Oncology's enterprise value requires a different approach. It uses Kura Oncology's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
As of November 29, 2022, Free Cash Flow is expected to decline to about (108.5 M). In addition to that, Enterprise Value is expected to decline to about 846.4 M.
Kura Oncology secures a last-minute Real Value of $20.97 per share. The latest price of the firm is $14.98. At this time, the firm appears to be undervalued. Our model forecasts the value of Kura Oncology from analyzing the firm fundamentals such as Shares Owned by Insiders of 2.77 %, current valuation of 617.23 M, and Return On Equity of (26.45) % as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend taking in undervalued stocks and trading overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
  
Kura Oncology Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Kura Oncology's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

Kura Oncology Most Recent Valuation Data

Price Book
2.37
Enterprise Value
571 M
Enterprise Value Ebitda
(4.24) 
Undervalued
Today 14.98
Please note that Kura Oncology's price fluctuation is not too volatile at this time. Calculation of the real value of Kura Oncology is based on 3 months time horizon. Increasing Kura Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Kura Oncology is useful when determining the fair value of the Kura Oncology stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Kura Oncology. Since Kura Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kura Oncology Stock. However, Kura Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
20.97
Real Value
24.82
Upside
Estimating the potential upside or downside of Kura Oncology helps investors to forecast how Kura Oncology stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kura Oncology more accurately as focusing exclusively on Kura Oncology's fundamentals will not take into account other important factors:
Earnings
Estimates (5)
LowProjected EPSHigh
-2.1-2.01-1.98
Details
Hype
Prediction
LowEstimated ValueHigh
10.7714.6218.47
Details
Naive
Forecast
LowNext ValueHigh
12.2716.1119.96
Details
5 Analysts
Consensus
LowTarget PriceHigh
32.0042.2556.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Kura Oncology's intrinsic value based on its ongoing forecasts of Kura Oncology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Kura Oncology's closest peers. When choosing an evaluation method for Kura Oncology, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Kura Oncology Investments

461.02 Million

Kura Oncology Valuation Drivers Correlation

Many accounts on the financial statements of Kura Oncology are highly interrelated and sometimes correlated. Consequently, when conducting Kura Oncology's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Kura Oncology
Click cells to compare fundamentals

Kura Oncology Valuation Trend

Knowing Kura Oncology's actual value is paramount for traders to make sound investment determinations. Kura Oncology's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Kura Oncology's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Kura Oncology's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Kura Oncology Market Cap

Kura Oncology is rated third overall in market capitalization category among related companies. Market capitalization of Biotechnology industry is now estimated at about 272.42 Billion. Kura Oncology adds roughly 989.02 Million in market capitalization claiming only tiny portion of stocks in Biotechnology industry.
Capitalization  Workforce  Total debt  Valuation  Revenue

Kura Oncology Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Kura Oncology's current stock value. Our valuation model uses many indicators to compare Kura Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kura Oncology competition to find correlations between indicators driving Kura Oncology's intrinsic value. More Info.
Kura Oncology is rated third overall in price to earning category among related companies. It is rated third overall in price to book category among related companies . The current year Price to Book Value is expected to grow to 2.24. Comparative valuation analysis is a catch-all model that can be used if you cannot value Kura Oncology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kura Oncology's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kura Oncology's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Kura Oncology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Kura Oncology and how it compares across the competition.

About Kura Oncology Valuation

The stock valuation mechanism determines the current worth of Kura Oncology on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Kura Oncology. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Kura Oncology based exclusively on its fundamental and basic technical indicators. By analyzing Kura Oncology's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Kura Oncology's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kura Oncology. We calculate exposure to Kura Oncology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Kura Oncology's related companies.
Fiscal Year End
December
Industry
Biotechnology
Concentration
Biotechnology
Full Time Employees
127.0
Service Category
Biotechnology
Employer Id Number
61-1547851
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 123 people.

Kura Oncology Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Kura Oncology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio25.19
Enterprise Value To Ebitda-4.60

Kura Oncology Current Valuation Indicators

Valuation refers to the process of determining the present value of Kura Oncology and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Kura Oncology we look at many different elements of the entity such as Kura Oncology's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Kura Oncology's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Kura Oncology's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Kura Oncology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Kura Oncology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Kura Oncology's worth.
Please see Correlation Analysis. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for analysis

When running Kura Oncology price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
998.8 M
Return On Assets
(0.17) 
Return On Equity
(0.28) 
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine Kura Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.